AI predicts cancer patients likely to discontinue treatment

Many breast cancer patients receiving adjuvant endocrine therapy choose to discontinue this treatment due to severe side effects, such as fatigue and insomnia.

Owkin, Sanofi, Gustave Roussy, Unicancer and Centre Georges Francois Leclerc have worked together to develop a model that uses AI to predict this early discontinuation.

The model was trained on data from more than 6,000 breast cancer patients undergoing adjuvant endocrine therapy from the CANTO cohort - provided by Unicancer and Gustave Roussy.

The data consisted of patients' medical and treatment history, as well as quality of life questionnaires which were completed after four months of endocrine therapy.

The data consisted of patients' medical and treatment history, as well as quality of life questionnaires.

Our model accurately identified patients most at risk of discontinuing their endocrine treatment.

This research, published in The Journal of the National Cancer Institute, could have an important impact on patient treatment and outcomes by guiding clinicians to provide these patients with alternative treatments or better clinical support to prevent and manage adverse reactions.

Watch our explainer video below to learn more.